Alembic Limited

ALEMBICLTDNSE

Market snapshot · 2026-08-12 04:31 UTC

₹84.25

₹-2.48 (-2.86%)

MARKET CAP

₹2.16K Cr

STOCK P/E

6.8x

52W HIGH

₹109.91

52W LOW

₹70.46

BOOK VALUE

₹95.22

EPS

₹12.36

ROE

13.27%

SECTOR

Health Care

DEBT/EQUITY

0.44

VOLUME

90,892

P/B RATIO

0.88x

PEG RATIO

—

Sector

Health Care

Themes

Pharmaceuticals

Dividend

AI Summary

✦ Clartha

Price Forecast

Current

—

High Target

—

Median Target

—

Low Target

—

Price history (1Y)

Analyst target range

Revenue Forecast

$ Cr

Mar '26Current$58.0

Sep 2026 ETrend estimate range

High$65.0Base$60.2Low$55.4

PastCurrentTrend estimate: Low / Base / High

EPS Forecast

$ / share

Mar '26Current$0.37

Sep 2026 ETrend estimate range

High$2.51Base$2.24Low$1.97

PastCurrentTrend estimate: Low / Base / High

Analyst price target unavailable from FMP/yfinance. Analyst recommendation consensus unavailable from FMP/yfinance. Valuation pillar unavailable from supplied valuation. Analyst pillar unavailable from FMP/yfinance.

Market Intelligence

Multi-factor synthesis of 5 key dimensions

Overall Outlook

Cautious

16%

Analyst Consensus

Unavailable

Analyst coverage unavailable

Mean upsideNot available

Fundamentals

Weakening

Fundamentals institutional score is 16 using growth durability 16.3.

Valuation

Unavailable

No valid valuation metrics were supplied.

Analyst Consensus

Unavailable

No usable analyst target or recommendation data was available.

Technical Structure

Unavailable

This data source has not been supplied for the decision payload.

Market Sentiment

Unavailable

This data source has not been supplied for the decision payload.

Signal Summary

Market intelligence remains Cautious. Available evidence provides partial support, while fundamentals remain considerations.

Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.

Fundamentals Weakening

Key Data Points

Mean Target PriceUnavailable

Mean UpsideNot available

Technical ScoreUnavailable

Fundamental Score16%

Data CoverageLow

Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.

Valuation Metrics

Forward Valuation Outlook

Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.

Historical valuation metrics are unavailable for this ticker right now.

Peers & Comparison

Sector: Health Care · Theme: Pharmaceuticals

Pharmaceuticals Peers1 peer

Avg P/E: 43.6x

Company	Rev. Growth	Margin	P/E	vs Avg	52W Perf.
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals	-17.4%	26.5%	43.6x Fair	0% vs avg	-23.9%

WHY THESE PEERS

ALEMBIC LIMITED trades at a discount (7.0x vs peer avg 43.6x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include BLUE JET HEALTHCARE LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.

Financials

Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.

Latest revenue

₹58 CrMar 2026

Latest net profit

₹9.53 CrMar 2026

Latest EPS

₹0.37Mar 2026

Net margin

33.9%Mar 2026

Performance

Bars show revenue and net profit. The line shows net margin.

Rs crore + margin %

Revenue
Net income
Net margin %

Earnings

Revenue is shown in crores. EPS is rupees per share.

Rs crore + Rs/share

Revenue
EPS

Revenue to profit conversion

Bridge from operating numbers to profit for the latest reported period.

Rs crore

Latest reported period: Mar 2026

Debt level and coverage

Debt, cash and free cash flow compared on the same crore scale.

Rs crore

Annual view

Debt
Free cash flow
Cash & equivalents

Results

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales +	36.10	35.65	31.15	37.94	47.51	49.08	51.10	55.97	58.22	47.89	54.04	72.28	57.73
Expenses +	23.32	25.54	21.53	24.79	24.14	29.63	32.72	30.26	32.21	29.31	31.52	45.23	38.18
Operating Profit	12.78	10.11	9.62	13.15	23.37	19.45	18.38	25.71	26.01	18.58	22.52	27.05	19.55
OPM %	35.40%	28.36%	30.88%	34.66%	49.19%	39.63%	35.97%	45.94%	44.68%	38.80%	41.67%	37.42%	33.86%
Other Income +	-8.64	2.59	47.86	2.21	1.95	1.89	65.59	4.25	2.78	3.46	64.80	2.10	2.41
Interest	0.04	0.05	0.05	0.26	0.33	0.34	0.51	0.52	0.45	0.42	0.40	0.37	0.37
Depreciation	1.61	1.74	1.77	2.57	1.38	2.41	2.59	2.59	2.66	2.70	2.72	3.34	3.25
Profit before tax	2.49	10.91	55.66	12.53	23.61	18.59	80.87	26.85	25.68	18.92	84.20	25.44	18.34
Tax %	-72.29%	13.11%	7.60%	9.90%	12.41%	9.41%	5.28%	4.32%	11.10%	9.51%	10.18%	12.50%	48.04%
Net Profit +	4.29	9.48	51.43	11.29	20.68	16.84	76.60	25.69	22.83	17.12	75.63	22.26	9.53
EPS in Rs	0.17	0.37	2.00	0.44	0.81	0.66	2.98	1.00	0.89	0.67	2.95	0.87	0.37
Raw PDF
YOY Sales Growth %	107.47%	68.72%	-14.40%	28.44%	31.61%	37.67%	64.04%	47.52%	22.54%	-2.42%	5.75%	29.14%	-0.84%
Material Cost %	31.61%	36.58%	31.59%	37.24%	25.15%	32.76%	36.61%	30.37%	29.85%	31.93%	29.31%	37.74%	31.21%
Employee Cost %	15.51%	17.59%	18.07%	14.71%	11.68%	15.75%	12.76%	11.72%	11.16%	16.35%	13.97%	14.28%	20.34%
Exceptional items	-10.61	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other income normal	1.97	2.59	47.86	2.21	1.95	1.89	65.59	4.25	2.78	3.46	64.80	2.10	2.41
Exceptional items AT	-11	0	0	0	0	0	0	0	0	0	0	0	0
Profit excl Excep	15	9	51	11	21	17	77	26	23	17	76	22	10
Profit for PE	15	9	51	11	21	17	77	26	23	17	76	22	10
Profit for EPS	4	9	51	11	21	17	77	26	23	17	76	22	10
YOY Profit Growth %	223%	161%	-16%	8%	39%	78%	49%	128%	10%	2%	-1%	-13%	-58%

All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).

Shareholding Pattern

Holder	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters +	70.88%	70.88%	70.88%	70.88%	70.88%
FIIs +	1.50%	1.38%	1.29%	1.25%	1.25%
DIIs +	0.05%	0.05%	0.05%	0.05%	0.06%
Public +	27.57%	27.68%	27.78%	27.81%	27.82%
Others	—	0.01%	—	0.01%	—

Jun 2026

Promoters +

FIIs +

DIIs +

Public +

Events Timeline

Annual Report FY26

FY2026PDFCompany Reports Open

Board Meeting Intimation for Considering Unaudited Financial Results For The Quarter Ended 30Th June, 2026